Literature DB >> 23831568

Alternative CD44 splicing in intestinal stem cells and tumorigenesis.

W Guo1, P S Frenette1.   

Abstract

As an important player in stem cells and cancer, CD44 is expressed in multiple isoforms via alternative mRNA splicing. Whether, and if so, how various isoforms play distinct roles in normal stem cells and tumorigenesis remains unclear. In this issue of Oncogene, Zeilstra et al. report studies showing that intestinal stem cells express a specific CD44 variant that promotes intestinal tumorigenesis induced by the activation of Wnt signaling, whereas the more commonly expressed standard CD44 isoform is not expressed by stem cells and does not promote tumor formation. This finding demonstrates an isoform-specific function of CD44 in intestinal stem cells and tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23831568     DOI: 10.1038/onc.2013.260

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  16 in total

1.  Generation of CD44 gene-deficient mouse derived induced pluripotent stem cells: CD44 gene-deficient iPSCs.

Authors:  Zhenwei Song; Qianqian Ji; Haijing Zhao; Yu Nie; Zuyong He; Yaosheng Chen; Peiqing Cong
Journal:  In Vitro Cell Dev Biol Anim       Date:  2014-06-21       Impact factor: 2.416

Review 2.  Alternative splicing of DNA damage response genes and gastrointestinal cancers.

Authors:  Bahityar Rahmutulla; Kazuyuki Matsushita; Fumio Nomura
Journal:  World J Gastroenterol       Date:  2014-12-14       Impact factor: 5.742

3.  CD44v6 expression in patients with stage II or stage III sporadic colorectal cancer is superior to CD44 expression for predicting progression.

Authors:  L H Zhao; Q L Lin; J Wei; Y L Huai; K J Wang; H Y Yan
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 4.  CD44 as a potential diagnostic tumor marker.

Authors:  Nawwaf S Basakran
Journal:  Saudi Med J       Date:  2015-03       Impact factor: 1.484

5.  Hyaluronan regulates bone morphogenetic protein-7-dependent prevention and reversal of myofibroblast phenotype.

Authors:  Adam C Midgley; Lucy Duggal; Robert Jenkins; Vincent Hascall; Robert Steadman; Aled O Phillips; Soma Meran
Journal:  J Biol Chem       Date:  2015-02-25       Impact factor: 5.157

Review 6.  Interactions between Hyaluronan and Its Receptors (CD44, RHAMM) Regulate the Activities of Inflammation and Cancer.

Authors:  Suniti Misra; Vincent C Hascall; Roger R Markwald; Shibnath Ghatak
Journal:  Front Immunol       Date:  2015-05-06       Impact factor: 7.561

7.  Primary Bovine Extra-Embryonic Cultured Cells: A New Resource for the Study of In Vivo Peri-Implanting Phenotypes and Mesoderm Formation.

Authors:  Isabelle Hue; Danièle Evain-Brion; Thierry Fournier; Séverine A Degrelle
Journal:  PLoS One       Date:  2015-06-12       Impact factor: 3.240

8.  Overexpression of CD44v8-10 in Colon Polyps-A Possible Key to Early Diagnosis.

Authors:  Milan Dastych; Frantisek Hubatka; Pavlina Turanek-Knotigova; Josef Masek; Radek Kroupa; Milan Raška; Jaroslav Turanek; Lubomir Prochazka
Journal:  Pathol Oncol Res       Date:  2021-03-30       Impact factor: 3.201

Review 9.  Utilization of Glycosaminoglycans/Proteoglycans as Carriers for Targeted Therapy Delivery.

Authors:  Suniti Misra; Vincent C Hascall; Ilia Atanelishvili; Ricardo Moreno Rodriguez; Roger R Markwald; Shibnath Ghatak
Journal:  Int J Cell Biol       Date:  2015-09-10

10.  The addition of rituximab to CHOP therapy alters the prognostic significance of CD44 expression.

Authors:  Xiaolei Wei; Meng Xu; Yongqiang Wei; Fen Huang; Tong Zhao; Xiangzhao Li; Ru Feng; B Hilda Ye
Journal:  J Hematol Oncol       Date:  2014-04-16       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.